Jean Arnault, director of Louis Vuitton’s watch division, has to contend with a tough luxury market and stubborn young consumers.

LVMH chief Bernard Arnault and Reliance Industries chairman Mukesh Ambani—the world’s fifth- and eighteenth-wealthiest people—attended President Donald Trump’s inauguration events Monday, marking a pair of surprise billionaire appearances at the event attended by a cadre of moguls worth well over $1 trillion.

The LVMH Moët Hennessy Louis Vuitton titan had prime seating near former Presidents Bill Clinton, George Bush and Barack Obama.

While the most talked-about fashion choice was the wide-brimmed accessory that obscured the first lady’s eyes, the most significant moment for the industry was the fact that Bernard Arnault, the CEO of LVMH,

From the color of their neckties to the fit of their suits, male politicians can be intentional with their choices.

Mr Trump is more transactional than presidents before him, which increases the risk of cronyism and self-dealing. But America’s economy, including its technology industry, is too unwieldy and dynamic to petrify into an actual oligarchy, whatever diplomats and departing presidents say. ■

LVMH, which is controlled by the family of multibillionaire Bernard Arnault, was a major sponsor of the Summer Games in Paris.

Bernard Arnault is outpacing Elon Musk and Mark Zuckerberg in wealth gain this year after signs of a rebound in luxury demand boosted LVMH stock.

LVMH has reclaimed its spot as the biggest company in Europe, overtaking Novo Nordisk after a significant drop in the drugmaker's shares. The cause? Concerns that the US governmen

“The golden age of America begins right now,” Trump proclaimed. For his billionaire backers, it has already begun.

The list of global businessmen and CEOs sitting on the dais for the inauguration adds up to more than $12 trillion in market value and more than $1 trillion in global wealth. From Elon Musk, to Bernard Arnault,

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.